Argos Therapeutics Inc.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2013 | $22 M | No. 5 | $10 to $50 million | equity, options | SEC | |
| Aug 2012 | $16 M | No. 4 | $10 to $50 million | equity, options | SEC | |
| Apr 2012 | $9 M | No. 3 | $2 to $10 million | equity | SEC | |
| Jul 2011 | $4 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Sep 2010 | $5 M | No. 1 | $2 to $10 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Argos Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2013).
SEC Form D · Aug 2013
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2013
That is all the official record says: Argos Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
25 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Aurora Ventures II LLC | Venture capital | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| AV II Argos Enrichment, LLC | Other | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Caisse de depot et placement du Quebec | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Charles A. Nicolette | Person | not stated | not stated | Held Series D and E preferred stock (Form 3, 2014) | SEC Form 3 |
| Forbion Co-Investment II Cooperatief U.A. | Fund or asset manager | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Frederick Miesowicz | Person | not stated | not stated | Held Series E preferred stock (Form 3, 2016) | SEC Form 3 |
| Green Cross Corp. | Company | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Harbinger Aurora QP Venture Fund LLC | Venture capital | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Harbinger Aurora Venture Fund LLC | Venture capital | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Intersouth Affiliates V LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Intersouth Partners IV LP /NC | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Intersouth Partners V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| JAIC USSII No. 1, LLC | Other | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Jeffrey D. Abbey | Person | not stated | not stated | Held Series C, D and E preferred stock, director (Form 3, 2014) | SEC Form 3 |
| LCC Legacy Holdings Inc. | Company | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lumira Capital I Limited Partnership | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lumira Capital I Quebec Limited Partnership | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Mizuho Capital No. 3 Limited Partnership | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Morningside Venture Investments Ltd | Venture capital | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Pharmstandard International S.A. | Company | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Public Joint Stock Co Pharmstandard | Other | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Striker Asia Opportunities Fund Corp | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| TFG USA, LLC | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| TVM V Life Science Ventures Gmbh & Co KG | Venture capital | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| TVM V Life Science Ventures Management GmbH & Co. KG | Venture capital | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 30 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Charles A. Nicolette | Executive officer | Aug 2013 |
| Douglas A. Plessinger | Executive officer | Aug 2013 |
| Frederick M. Miesowicz | Executive officer | Aug 2013 |
| Jeffrey D. Abbey | Executive officer | Aug 2013 |
| Lori A. Harrelson | Executive officer | Aug 2013 |
| Andrei A. Petrov | Director | Aug 2013 |
| Brian R. Underdown | Director | Aug 2013 |
| David A. Gryska | Director | Aug 2013 |
| Hubert D. Birner | Director | Aug 2013 |
| Jean A. Lamarre | Director | Aug 2013 |
| Jeffrey D. Abbey | Director | Aug 2013 |
| Philip R. Tracy | Director | Aug 2013 |
| Sander D. van Deventer | Director | Aug 2013 |
| B. Jefferson Clark | Director | Apr 2012 |
| Monique A. Laliberte | Director | Apr 2012 |
| Sander Jefferson van Deventer | Director | Apr 2012 |
| Michel Jefferson Greco | Director | Jul 2011 |
| Ines Jefferson Holzbaur | Director | Sep 2010 |